Millendo Therapeutics SAS
🇫🇷France
Clinical Trials
8
Active:6
Completed:1
Trial Phases
2 Phases
Phase 1:6
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (75.0%)Phase 2
2 (25.0%)Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome
Phase 2
Terminated
- Conditions
- Prader-Willi SyndromeHyperphagia
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Millendo Therapeutics SAS
- Target Recruit Count
- 158
- Registration Number
- NCT03790865
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California - Irvine Medical Center, Orange, California, United States
🇺🇸Rady Children's Hospital - San Diego, San Diego, California, United States
News
No news found